Cantor Fitzgerald Reaffirms “Overweight” Rating for Veru (NASDAQ:VERU)

Veru (NASDAQ:VERUGet Rating)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a note issued to investors on Friday, Zacks.com reports.

A number of other research firms have also weighed in on VERU. Zacks Investment Research lowered shares of Veru from a “buy” rating to a “hold” rating in a report on Thursday, April 21st. HC Wainwright raised their price objective on shares of Veru from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, April 12th. TheStreet raised shares of Veru from a “d+” rating to a “c” rating in a report on Friday, April 29th. Oppenheimer raised their price objective on shares of Veru from $25.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday, April 12th. Finally, Jefferies Financial Group raised their price objective on shares of Veru from $33.00 to $55.00 in a report on Friday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Veru has an average rating of “Buy” and an average price target of $32.75.

VERU opened at $13.00 on Friday. The company has a fifty day simple moving average of $8.17 and a 200 day simple moving average of $7.06. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -65.00 and a beta of -0.57. Veru has a twelve month low of $4.34 and a twelve month high of $17.50.

Veru (NASDAQ:VERUGet Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Veru had a negative net margin of 26.68% and a negative return on equity of 10.62%. During the same quarter last year, the business earned ($0.04) EPS. Analysts forecast that Veru will post -0.34 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of VERU. Royal Bank of Canada increased its stake in Veru by 34.3% during the 2nd quarter. Royal Bank of Canada now owns 13,292 shares of the company’s stock valued at $107,000 after buying an additional 3,397 shares during the period. SG Americas Securities LLC acquired a new position in Veru during the 3rd quarter valued at about $245,000. PNC Financial Services Group Inc. increased its stake in Veru by 833.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,600 shares of the company’s stock valued at $49,000 after buying an additional 5,000 shares during the period. Swiss National Bank increased its stake in Veru by 2.0% during the 3rd quarter. Swiss National Bank now owns 140,900 shares of the company’s stock valued at $1,202,000 after buying an additional 2,700 shares during the period. Finally, Principal Financial Group Inc. acquired a new position in Veru during the 3rd quarter valued at about $97,000. Institutional investors own 29.11% of the company’s stock.

About Veru (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Read More

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.